Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
THE BEST BLACK FRIDAY DEAL YET (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Airbnb has a plan to fix cleaning fees
THE BEST BLACK FRIDAY DEAL YET (Ad)
Railway workers in Austria to strike Monday in pay standoff
Saudi viewers angry over apparent ban on World Cup streaming
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
THE BEST BLACK FRIDAY DEAL YET (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Airbnb has a plan to fix cleaning fees
THE BEST BLACK FRIDAY DEAL YET (Ad)
Railway workers in Austria to strike Monday in pay standoff
Saudi viewers angry over apparent ban on World Cup streaming
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
THE BEST BLACK FRIDAY DEAL YET (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Airbnb has a plan to fix cleaning fees
THE BEST BLACK FRIDAY DEAL YET (Ad)
Railway workers in Austria to strike Monday in pay standoff
Saudi viewers angry over apparent ban on World Cup streaming
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
THE BEST BLACK FRIDAY DEAL YET (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Airbnb has a plan to fix cleaning fees
THE BEST BLACK FRIDAY DEAL YET (Ad)
Railway workers in Austria to strike Monday in pay standoff
Saudi viewers angry over apparent ban on World Cup streaming

ANI Pharmaceuticals - ANIP Stock Forecast, Price & News

$41.66
+1.47 (+3.66%)
(As of 11/25/2022 04:00 PM ET)
Add
Compare
Today's Range
$39.49
$41.66
50-Day Range
$31.10
$41.66
52-Week Range
$22.31
$51.69
Volume
48,911 shs
Average Volume
69,356 shs
Market Capitalization
$727.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$49.00

ANI Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
17.6% Upside
$49.00 Price Target
Short Interest
Bearish
4.57% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.98
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
240.63%
From $0.64 to $2.18 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.22 out of 5 stars

Medical Sector

423rd out of 1,044 stocks

Pharmaceutical Preparations Industry

201st out of 510 stocks

ANIP stock logo

About ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Receive ANIP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ANIP Stock News Headlines

ANI Pharmaceuticals, Inc. Q3 Earnings Summary
ANI Pharmaceuticals Appoints Krista Davis as...
Full-Year 2022 Guidance:
ANI Pharmaceuticals Q2 2022 Earnings Preview
See More Headlines
Receive ANIP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ANIP Company Calendar

Last Earnings
10/31/2021
Today
11/27/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/21/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ANIP
Previous Symbol
NASDAQ:BPAX
Employees
601
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$49.00
High Stock Price Forecast
$50.00
Low Stock Price Forecast
$48.00
Forecasted Upside/Downside
+17.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-42,600,000.00
Pretax Margin
-31.01%

Debt

Sales & Book Value

Annual Sales
$216.14 million
Cash Flow
$4.71 per share
Book Value
$17.85 per share

Miscellaneous

Free Float
12,715,000
Market Cap
$727.80 million
Optionable
Optionable
Beta
1.06

Key Executives

  • Mr. Nikhil LalwaniMr. Nikhil Lalwani (Age 44)
    Pres, CEO & Director
    Comp: $2.17M
  • Mr. Stephen P. CareyMr. Stephen P. Carey (Age 51)
    CFO, Sr. VP of Fin. & Corp. Sec.
    Comp: $1.11M
  • Mr. James G. Marken (Age 59)
    Sr. VP of Operations & Product Devel.
    Comp: $709.02k
  • Mr. Christopher K. Mutz (Age 50)
    Head of Rare Disease
    Comp: $643.58k
  • Mr. Ori Gutwerg (Age 48)
    Sr. VP of Generics
    Comp: $710.74k
  • Mr. Muthusamy Shanmugam MS R.Ph.Mr. Muthusamy Shanmugam MS R.Ph. (Age 54)
    Head of R&D, COO of Novitium Operations & Director
  • Ms. Meredith W. Cook
    Sr. VP, Gen. Counsel & Corp. Sec.
  • Mr. Chad Gassert (Age 46)
    Sr. VP of Corp. Devel. & Strategy
  • Ms. Krista L. Davis
    Chief HR Officer
  • Ms. Elizabeth Powell J.D.
    Chief Compliance Officer & Head of Legal of Rare Disease













ANIP Stock - Frequently Asked Questions

Should I buy or sell ANI Pharmaceuticals stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANIP shares.
View ANIP analyst ratings
or view top-rated stocks.

What is ANI Pharmaceuticals' stock price forecast for 2023?

3 Wall Street analysts have issued 1 year target prices for ANI Pharmaceuticals' stock. Their ANIP share price forecasts range from $48.00 to $50.00. On average, they anticipate the company's stock price to reach $49.00 in the next year. This suggests a possible upside of 17.6% from the stock's current price.
View analysts price targets for ANIP
or view top-rated stocks among Wall Street analysts.

How have ANIP shares performed in 2022?

ANI Pharmaceuticals' stock was trading at $46.08 on January 1st, 2022. Since then, ANIP shares have decreased by 9.6% and is now trading at $41.66.
View the best growth stocks for 2022 here
.

When is ANI Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 21st 2023.
View our ANIP earnings forecast
.

How were ANI Pharmaceuticals' earnings last quarter?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) issued its quarterly earnings results on Sunday, October, 31st. The specialty pharmaceutical company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.70 by $0.31. The specialty pharmaceutical company had revenue of $52.06 million for the quarter, compared to the consensus estimate of $50.30 million. ANI Pharmaceuticals had a positive trailing twelve-month return on equity of 2.65% and a negative net margin of 23.95%. During the same quarter in the prior year, the company posted $0.70 earnings per share.

What guidance has ANI Pharmaceuticals issued on next quarter's earnings?

ANI Pharmaceuticals updated its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided earnings per share (EPS) guidance of $1.34-$1.62 for the period, compared to the consensus earnings per share estimate of $1.37. The company issued revenue guidance of $295.00 million-$315.00 million, compared to the consensus revenue estimate of $302.88 million.

What is Arthur Przbyl's approval rating as ANI Pharmaceuticals' CEO?

5 employees have rated ANI Pharmaceuticals Chief Executive Officer Arthur Przbyl on Glassdoor.com. Arthur Przbyl has an approval rating of 100% among the company's employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at ANI Pharmaceuticals to a friend.

What other stocks do shareholders of ANI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Broadcom (AVGO), Cisco Systems (CSCO), Exelixis (EXEL) and Intel (INTC).

What is ANI Pharmaceuticals' stock symbol?

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

Who are ANI Pharmaceuticals' major shareholders?

ANI Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (11.04%), Vanguard Group Inc. (4.52%), Dimensional Fund Advisors LP (3.01%), Emerald Advisers LLC (2.62%), State Street Corp (2.60%) and Global Alpha Capital Management Ltd. (2.40%). Insiders that own company stock include James G Marken, Jeanne Thoma, Muthusamy Shanmugam, Nikhil Lalwani, Patrick D Walsh and Thomas Haughey.
View institutional ownership trends
.

How do I buy shares of ANI Pharmaceuticals?

Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ANI Pharmaceuticals' stock price today?

One share of ANIP stock can currently be purchased for approximately $41.66.

How much money does ANI Pharmaceuticals make?

ANI Pharmaceuticals (NASDAQ:ANIP) has a market capitalization of $727.80 million and generates $216.14 million in revenue each year. The specialty pharmaceutical company earns $-42,600,000.00 in net income (profit) each year or ($4.48) on an earnings per share basis.

How many employees does ANI Pharmaceuticals have?

The company employs 601 workers across the globe.

How can I contact ANI Pharmaceuticals?

ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The official website for the company is www.anipharmaceuticals.com. The specialty pharmaceutical company can be reached via phone at (218) 634-3500, via email at ir@anipharmaceuticals.com, or via fax at 218-634-3540.

This page (NASDAQ:ANIP) was last updated on 11/27/2022 by MarketBeat.com Staff